IL128524A0 - Ether muscarinic antagonists - Google Patents
Ether muscarinic antagonistsInfo
- Publication number
- IL128524A0 IL128524A0 IL12852497A IL12852497A IL128524A0 IL 128524 A0 IL128524 A0 IL 128524A0 IL 12852497 A IL12852497 A IL 12852497A IL 12852497 A IL12852497 A IL 12852497A IL 128524 A0 IL128524 A0 IL 128524A0
- Authority
- IL
- Israel
- Prior art keywords
- optionally substituted
- alkyl
- formula
- muscarinic antagonists
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70072296A | 1996-08-15 | 1996-08-15 | |
| PCT/US1997/013894 WO1998006697A1 (en) | 1996-08-15 | 1997-08-13 | Ether muscarinic antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL128524A0 true IL128524A0 (en) | 2000-01-31 |
Family
ID=24814614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12852497A IL128524A0 (en) | 1996-08-15 | 1997-08-13 | Ether muscarinic antagonists |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0922029B1 (zh) |
| JP (1) | JP3390179B2 (zh) |
| KR (1) | KR20000029976A (zh) |
| CN (1) | CN1155574C (zh) |
| AT (1) | ATE297381T1 (zh) |
| AU (1) | AU732096B2 (zh) |
| BR (1) | BR9711061A (zh) |
| CA (1) | CA2263167C (zh) |
| CZ (1) | CZ43399A3 (zh) |
| DE (1) | DE69733478T2 (zh) |
| ES (1) | ES2241053T3 (zh) |
| HU (1) | HUP9904363A3 (zh) |
| IL (1) | IL128524A0 (zh) |
| NO (1) | NO990671L (zh) |
| NZ (1) | NZ334017A (zh) |
| PL (1) | PL331536A1 (zh) |
| SK (1) | SK20199A3 (zh) |
| TR (1) | TR199900314T2 (zh) |
| WO (1) | WO1998006697A1 (zh) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| NZ525108A (en) * | 1998-03-31 | 2005-02-25 | Acadia Pharm Inc | Compounds with activity on muscarinic receptors |
| IL143733A0 (en) | 1998-12-23 | 2002-04-21 | Orphan Medical Inc | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| US6387930B1 (en) | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
| IL145742A0 (en) * | 1999-05-04 | 2002-07-25 | Schering Corp | Piperidine derivatives useful as ccr5 antagonists |
| US6635646B1 (en) | 1999-05-04 | 2003-10-21 | Schering Corporation | Pegylated interferon alfa-CCR5 antagonist combination HIV therapy |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| US7718650B2 (en) | 2001-05-11 | 2010-05-18 | Biovitrum Ab | Aryl sulfonamide compounds for treating obesity |
| EP1406884A1 (en) | 2001-05-11 | 2004-04-14 | Biovitrum Ab | Arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders |
| WO2003004487A1 (en) | 2001-07-02 | 2003-01-16 | Astrazeneca Ab | Piperidine derivatives useful as modulators of chemokine receptor activity |
| GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
| GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
| KR100579813B1 (ko) * | 2001-10-16 | 2006-05-12 | 주식회사 에스티씨나라 | 피페리딘 유도체, 이의 제조방법 및 이를 포함하는 치매치료용 약학적 조성물 |
| DE10201550A1 (de) * | 2002-01-17 | 2003-07-31 | Merck Patent Gmbh | Phenoxy-Piperidine |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SI2389937T1 (sl) * | 2002-06-14 | 2018-10-30 | Toyama Chemical Co., Ltd, | Farmacevtska sestava za izboljšanje možganske funkcije |
| SE0202838D0 (sv) * | 2002-09-24 | 2002-09-24 | Astrazeneca Ab | Chemical compounds |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| SE0302956D0 (sv) * | 2003-11-07 | 2003-11-07 | Astrazeneca Ab | Chemical compounds |
| WO2006126948A1 (en) * | 2005-05-27 | 2006-11-30 | Astrazeneca Ab | Piperidines for the treatment of chemokine mediated diseases |
| TW200722419A (en) * | 2005-05-27 | 2007-06-16 | Astrazeneca Ab | Chemical compounds |
| EP1912941B1 (en) | 2005-07-21 | 2012-11-14 | AstraZeneca AB | Piperidine derivatives |
| DE102008008838A1 (de) | 2008-02-13 | 2009-08-20 | Bayer Healthcare Ag | Cycloalkoxy-substituierte 4-Phenyl-3,5-dicyanopyridine und ihre Verwendung |
| US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| KR20120123089A (ko) | 2010-02-16 | 2012-11-07 | 화이자 인코포레이티드 | 5-ＨＴ₄ 수용체의 부분 효능제인 (Ｒ)-4-((4-((4-(테트라히드로푸란-3-일옥시)벤조［ｄ］이속사졸-3-일옥시)메틸)피페리딘-1-일)메틸)테트라히드로-2Ｈ-피란-4-올 |
| SG11201807516UA (en) | 2016-03-17 | 2018-09-27 | Hoffmann La Roche | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar |
| WO2018112840A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2018112843A1 (en) * | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| JP3064425B2 (ja) * | 1995-09-15 | 2000-07-12 | ノイロサーチ アクティーゼルスカブ | カルシウムチャンネル・ブロッカーとしてのピペリジン化合物 |
-
1997
- 1997-08-13 TR TR1999/00314T patent/TR199900314T2/xx unknown
- 1997-08-13 JP JP50985498A patent/JP3390179B2/ja not_active Expired - Fee Related
- 1997-08-13 ES ES97937152T patent/ES2241053T3/es not_active Expired - Lifetime
- 1997-08-13 CA CA002263167A patent/CA2263167C/en not_active Expired - Fee Related
- 1997-08-13 IL IL12852497A patent/IL128524A0/xx unknown
- 1997-08-13 NZ NZ334017A patent/NZ334017A/xx unknown
- 1997-08-13 KR KR1019997001227A patent/KR20000029976A/ko not_active Application Discontinuation
- 1997-08-13 PL PL97331536A patent/PL331536A1/xx unknown
- 1997-08-13 SK SK201-99A patent/SK20199A3/sk unknown
- 1997-08-13 CN CNB971985588A patent/CN1155574C/zh not_active Expired - Fee Related
- 1997-08-13 EP EP97937152A patent/EP0922029B1/en not_active Expired - Lifetime
- 1997-08-13 WO PCT/US1997/013894 patent/WO1998006697A1/en active IP Right Grant
- 1997-08-13 DE DE69733478T patent/DE69733478T2/de not_active Expired - Fee Related
- 1997-08-13 AT AT97937152T patent/ATE297381T1/de not_active IP Right Cessation
- 1997-08-13 HU HU9904363A patent/HUP9904363A3/hu unknown
- 1997-08-13 CZ CZ99433A patent/CZ43399A3/cs unknown
- 1997-08-13 BR BR9711061A patent/BR9711061A/pt unknown
- 1997-08-13 AU AU39732/97A patent/AU732096B2/en not_active Ceased
-
1999
- 1999-02-12 NO NO990671A patent/NO990671L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR9711061A (pt) | 1999-08-17 |
| JP2000500786A (ja) | 2000-01-25 |
| CA2263167C (en) | 2006-02-14 |
| SK20199A3 (en) | 2000-03-13 |
| HUP9904363A2 (hu) | 2000-11-28 |
| TR199900314T2 (xx) | 1999-05-21 |
| NZ334017A (en) | 2000-04-28 |
| WO1998006697A1 (en) | 1998-02-19 |
| CA2263167A1 (en) | 1998-02-19 |
| EP0922029A1 (en) | 1999-06-16 |
| EP0922029B1 (en) | 2005-06-08 |
| NO990671D0 (no) | 1999-02-12 |
| HUP9904363A3 (en) | 2000-12-28 |
| NO990671L (no) | 1999-04-15 |
| AU3973297A (en) | 1998-03-06 |
| PL331536A1 (en) | 1999-07-19 |
| DE69733478D1 (de) | 2005-07-14 |
| JP3390179B2 (ja) | 2003-03-24 |
| CN1155574C (zh) | 2004-06-30 |
| ES2241053T3 (es) | 2005-10-16 |
| CN1232453A (zh) | 1999-10-20 |
| CZ43399A3 (cs) | 1999-07-14 |
| DE69733478T2 (de) | 2005-11-03 |
| KR20000029976A (ko) | 2000-05-25 |
| AU732096B2 (en) | 2001-04-12 |
| ATE297381T1 (de) | 2005-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL128524A0 (en) | Ether muscarinic antagonists | |
| MY133992A (en) | Muscarinic antagonists | |
| NO990551L (no) | Piperidin- og piperazinderivater, og deres anvendelse som muskarine antagonister | |
| IL117149A0 (en) | Muscarinic antagonists | |
| IL127858A0 (en) | Muscarinic antagonists | |
| AU3581097A (en) | 1,4-di-sustituted piperidines as muscarinic antagonists | |
| WO2001090106A3 (en) | Tryasolyl tropane derivatives as ccr5 modulators | |
| PL361361A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| HK1010881A1 (en) | Derivatives of azetidine and pyrrolidine | |
| PL361282A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| AP1816A (en) | 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists. | |
| MY133445A (en) | 2-arylethyl-(piperidin-4-ylmethyl)amine derivetives | |
| ES2087038A1 (es) | Nuevas piperidinas con actividad antagonista del paf. | |
| EG20726A (en) | Process for preparing of galanthamine derivatives as acetylchol inc-sterase inhibitors | |
| HUT57773A (en) | Process for produicng n-(aminocarbonyl)-carbamates related to physostigmine, as well as pharmaceutical compositions comprising such compounds | |
| CA2384018A1 (en) | Muscarinic antagonists | |
| NZ543068A (en) | Substituted 4-(alkyl-amide)-piperidine derivatives, processes for their preparation, and pharmaceutical compositions containing them | |
| RU94032285A (ru) | Цефалоспориновые соединения, способ их получения, фармацевтическая композиция | |
| CA2180660A1 (en) | Novel piperidine derivatives with paf antagonist activity | |
| ECSP003505A (es) | Derivados de 4-fenil- pirimidina | |
| MY103509A (en) | Indole derivatives. |